Phosphatase POPX2 interferes with cell cycle by interacting with Chk1

被引:5
作者
Kim, Pu Rum [1 ]
Koon, Yen Ling [2 ,3 ]
Lee, Raphael Tze Chuen [3 ]
Azizan, Farouq [1 ]
Koh, Dylan Hong Zheng [1 ]
Chiam, Keng-Hwee [3 ]
Koh, Cheng-Gee [1 ]
机构
[1] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore
[2] Nanyang Technol Univ, Interdisciplinary Grad Sch, Singapore, Singapore
[3] ASTAR, Biopolis, Bioinformat Inst, Singapore, Singapore
关键词
Protein-Protein Interactions; POPX2; phosphatase; DNA damage pathway; Chk1; kinase; G1-S checkpoint; DNA-DAMAGE RESPONSE; CHECKPOINT KINASE 1; PROTEIN PHOSPHATASE; DOMAIN INTERACTIONS; PATHWAY; ATR; DEPHOSPHORYLATES; PHOSPHORYLATION; INHIBITION; ACTIVATION;
D O I
10.1080/15384101.2020.1711577
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Protein-protein interaction network analysis plays critical roles in predicting the functions of target proteins. In this study, we used a combination of SILAC-MS proteomics and bioinformatic approaches to identify Checkpoint Kinase 1 (Chk1) as a possible POPX2 phosphatase interacting protein. POPX2 is a PP2C phosphatase that has been implicated in cancer cell invasion and migration. From the Domain-Domain Interaction (DDI) database, we first determined that the PP2C phosphatase domain interacts with Pkinase domain. Subsequently, 46 proteins with Pkinase domain were identified from POPX2 SILAC-MS data. We then narrowed down the leads and confirmed the biological interaction between Chk1 and POPX2. We also found that Chk1 is a substrate of POPX2. Chk1 is a key regulator of the cell cycle and is activated when the cell suffers DNA damage. Our approach has led us to identify POPX2 as a regulator of Chk1 and can interfere with the normal function of Chk1 at G1-S transition of the cell cycle in response to DNA damage.
引用
收藏
页码:405 / 418
页数:14
相关论文
共 51 条
[11]   Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53 [J].
Gadhikar, Mayur A. ;
Sciuto, Maria Rita ;
Alves, Marcus Vinicius Ortega ;
Pickering, Curtis R. ;
Osman, Abdullah A. ;
Neskey, David M. ;
Zhao, Mei ;
Fitzgerald, Alison L. ;
Myers, Jeffrey N. ;
Frederick, Mitchell J. .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) :1860-1873
[12]   Regulation of the TAK1 signaling pathway by protein phosphatase 2C [J].
Hanada, M ;
Ninomiya-Tsuji, J ;
Komaki, K ;
Ohnishi, M ;
Katsura, K ;
Kanamaru, R ;
Matsumoto, K ;
Tamura, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (08) :5753-5759
[13]   The DNA damage response: Ten years after [J].
Harper, J. Wade ;
Elledge, Stephen J. .
MOLECULAR CELL, 2007, 28 (05) :739-745
[14]   Regulation of the multifunctional Ca2+/calmodulin-dependent protein kinase II by the PP2C phosphatase PPM1F in fibroblasts [J].
Harvey, BP ;
Banga, SS ;
Ozer, HL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (23) :24889-24898
[15]   A novel protein phosphatase that dephosphorylates and regulates Ca2+/calmodulin-dependent protein kinase II [J].
Ishida, A ;
Kameshita, I ;
Fujisawa, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) :1904-1910
[16]   Evolutionary conservation of domain-domain interactions [J].
Itzhaki, Zohar ;
Akiva, Eyal ;
Altuvia, Yael ;
Margalit, Hanah .
GENOME BIOLOGY, 2006, 7 (12)
[17]   MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability [J].
Katoh, Kazutaka ;
Standley, Daron M. .
MOLECULAR BIOLOGY AND EVOLUTION, 2013, 30 (04) :772-780
[18]   Predicting Protein-Protein Interactions from the Molecular to the Proteome Level [J].
Keskin, Ozlem ;
Tuncbag, Nurcan ;
Gursoy, Attila .
CHEMICAL REVIEWS, 2016, 116 (08) :4884-4909
[19]   The p21-activated kinase PAK is negatively regulated by POPX1 and POPX2, a pair of serine/threonine phosphatases of the PP2C family [J].
Koh, CG ;
Tan, EJ ;
Manser, E ;
Lim, L .
CURRENT BIOLOGY, 2002, 12 (04) :317-321
[20]   mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells [J].
Koppenhafer, Stacia L. ;
Goss, Kelli L. ;
Terry, William W. ;
Gordon, David J. .
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (12) :2676-2688